Hazim Allos
Research Subjects
Hazim Allos has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Amr Mansouri
Transplantation Research Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
2 shared publications - Ina Sulkaj
Transplantation Research Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
2 shared publications - Jamil R. Azzi
Department of Medicine, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
2 shared publications - John Y. Choi
Transplant Research Center, Division of Renal Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States of America
2 shared publications - Juliano Alhaddad
Department of Medicine, Boston Medical Center Brighton, Boston, USA
2 shared publications - Siawosh K. Eskandari
Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Springer Nature in Neurocritical Care
- p. 1-9
Etiologies, Clinical Characteristics, and Prognostic Impact of Increased Intracranial Pressure in Adults with Encephalitis
Background: Encephalitis may present with increased intracranial pressure (ICP) levels but data on its impact is unknown. We aimed to highlight the associated etiologies, clinical characteristics, and prognostic significance of increased ICP in encephalitis. Methods: This multicenter retrospective study analyzed adults with encephalitis across 18 hospitals in Houston and Baltimore from 2002 to 2023, describing factors associated with measurement of intracranial pressure and variables associated with elevated intracranial pressure, defined by a lumbar puncture (LP) opening pressure (OP) > 30 cmH 2 O. Results: Among 647 adults with encephalitis, the most common etiologies were unknown (38%), viral (32.9%), autoimmune (18.1%), bacterial (6.2%), and fungal (2.5%), and these did not differ significantly between patients with or without OP measurement or between those with normal versus elevated OP. A total of 298 patients (46%) had OP measured; of these, 242 (81.2%) had an OP < 30 cmH 2 O and 56 (18.8%) had elevated OP (≥ 30 cmH 2 O). Patients were more likely to undergo OP measurement if they were febrile, immunocompromised, or had abnormal brain magnetic resonance imaging (MRI) or electroencephalogram (EEG) findings ( p < 0.05). Patients with elevated OP more frequently presented with nuchal rigidity, were less likely to have abnormal EEG findings, had longer hospital length of stay, longer duration of mechanical ventilation, and worse clinical outcomes as defined by a Glasgow Outcome Scale score < 4 ( p < 0.05). In this cohort, only three patients received nonconservative management of elevated ICP. Conclusions: OP was measured in fewer than half of adults with encephalitis. Elevated OP was associated with longer hospital stays, prolonged mechanical ventilation, and worse clinical outcomes, yet was infrequently managed with targeted interventions. Notably, all three patients who underwent nonconservative ICP management survived, with two achieving complete or near-complete neurological recovery, suggesting potential benefit from targeted intervention in select cases.
- 21 July 2026
- Published by Springer Nature in Neurocritical Care
- p. 1-9
Open AccessEtiologies, Clinical Characteristics, and Prognostic Impact of Increased Intracranial Pressure in Adults with Encephalitis
Background: Encephalitis may present with increased intracranial pressure (ICP) levels but data on its impact is unknown. We aimed to highlight the associated etiologies, clinical characteristics, and prognostic significance of increased ICP in encephalitis. Methods: This multicenter retrospective study analyzed adults with encephalitis across 18 hospitals in Houston and Baltimore from 2002 to 2023, describing factors associated with measurement of intracranial pressure and variables associated with elevated intracranial pressure, defined by a lumbar puncture (LP) opening pressure (OP) > 30 cmH 2 O. Results: Among 647 adults with encephalitis, the most common etiologies were unknown (38%), viral (32.9%), autoimmune (18.1%), bacterial (6.2%), and fungal (2.5%), and these did not differ significantly between patients with or without OP measurement or between those with normal versus elevated OP. A total of 298 patients (46%) had OP measured; of these, 242 (81.2%) had an OP < 30 cmH 2 O and 56 (18.8%) had elevated OP (≥ 30 cmH 2 O). Patients were more likely to undergo OP measurement if they were febrile, immunocompromised, or had abnormal brain magnetic resonance imaging (MRI) or electroencephalogram (EEG) findings ( p < 0.05). Patients with elevated OP more frequently presented with nuchal rigidity, were less likely to have abnormal EEG findings, had longer hospital length of stay, longer duration of mechanical ventilation, and worse clinical outcomes as defined by a Glasgow Outcome Scale score < 4 ( p < 0.05). In this cohort, only three patients received nonconservative management of elevated ICP. Conclusions: OP was measured in fewer than half of adults with encephalitis. Elevated OP was associated with longer hospital stays, prolonged mechanical ventilation, and worse clinical outcomes, yet was infrequently managed with targeted interventions. Notably, all three patients who underwent nonconservative ICP management survived, with two achieving complete or near-complete neurological recovery, suggesting potential benefit from targeted intervention in select cases.
- 11 November 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (569)
Regulatory T cells engineered with TCR signaling–responsive IL-2 nanogels suppress alloimmunity in sites of antigen encounter
Adoptive cell transfer of ex vivo expanded regulatory T cells (Tregs) has shown immense potential in animal models of auto- and alloimmunity. However, the effective translation of such Treg therapies to the clinic has been slow. Because Treg homeostasis is known to require continuous T cell receptor (TCR) ligation and exogenous interleukin-2 (IL-2), some investigators have explored the use of low-dose IL-2 injections to increase endogenous Treg responses. Systemic IL-2 immunotherapy, however, can also lead to the activation of cytotoxic T lymphocytes and natural killer cells, causing adverse therapeutic outcomes. Here, we describe a drug delivery platform, which can be engineered to autostimulate Tregs with IL-2 in response to TCR-dependent activation, and thus activate these cells in sites of antigen encounter. To this end, protein nanogels (NGs) were synthesized with cleavable bis(N-hydroxysuccinimide) cross-linkers and IL-2/Fc fusion (IL-2) proteins to form particles that release IL-2 under reducing conditions, as found at the surface of T cells receiving stimulation through the TCR. Tregs surface-conjugated with IL-2 NGs were found to have preferential, allograft-protective effects relative to unmodified Tregs or Tregs stimulated with systemic IL-2. We demonstrate that murine and human NG–modified Tregs carrying an IL-2 cargo perform better than conventional Tregs in suppressing alloimmunity in murine and humanized mouse allotransplantation models. In all, the technology presented in this study has the potential to improve Treg transfer therapy by enabling the regulated spatiotemporal provision of IL-2 to antigen-primed Tregs.
- 11 November 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (569)
Regulatory T cells engineered with TCR signaling–responsive IL-2 nanogels suppress alloimmunity in sites of antigen encounter
Adoptive cell transfer of ex vivo expanded regulatory T cells (Tregs) has shown immense potential in animal models of auto- and alloimmunity. However, the effective translation of such Treg therapies to the clinic has been slow. Because Treg homeostasis is known to require continuous T cell receptor (TCR) ligation and exogenous interleukin-2 (IL-2), some investigators have explored the use of low-dose IL-2 injections to increase endogenous Treg responses. Systemic IL-2 immunotherapy, however, can also lead to the activation of cytotoxic T lymphocytes and natural killer cells, causing adverse therapeutic outcomes. Here, we describe a drug delivery platform, which can be engineered to autostimulate Tregs with IL-2 in response to TCR-dependent activation, and thus activate these cells in sites of antigen encounter. To this end, protein nanogels (NGs) were synthesized with cleavable bis(N-hydroxysuccinimide) cross-linkers and IL-2/Fc fusion (IL-2) proteins to form particles that release IL-2 under reducing conditions, as found at the surface of T cells receiving stimulation through the TCR. Tregs surface-conjugated with IL-2 NGs were found to have preferential, allograft-protective effects relative to unmodified Tregs or Tregs stimulated with systemic IL-2. We demonstrate that murine and human NG–modified Tregs carrying an IL-2 cargo perform better than conventional Tregs in suppressing alloimmunity in murine and humanized mouse allotransplantation models. In all, the technology presented in this study has the potential to improve Treg transfer therapy by enabling the regulated spatiotemporal provision of IL-2 to antigen-primed Tregs.
- Open Access
- 28 February 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (11) , 6042-6046
Regulatory CD8 T cells that recognize Qa-1 expressed by CD4 T-helper cells inhibit rejection of heart allografts
Significance: There is increasing evidence that CD8 + regulatory T cells (CD8 Treg) can modulate the immune response in the context of autoimmune disease, infection, and cancer. Here we asked whether this regulatory mechanism might control the host response to transplanted heart allografts. We report that CD8 Treg that recognize Qa-1, the murine homolog of HLA-E, strongly inhibits host production of antibodies specific for the donor organ. Since the production of antidonor antibodies is currently a major barrier to successful transplantation, identification of this Qa-1/HLA-E-dependent pathway may pave the way to approaches to this pressing clinical problem.
- 28 February 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (11) , 6042-6046
Open AccessRegulatory CD8 T cells that recognize Qa-1 expressed by CD4 T-helper cells inhibit rejection of heart allografts
Significance: There is increasing evidence that CD8 + regulatory T cells (CD8 Treg) can modulate the immune response in the context of autoimmune disease, infection, and cancer. Here we asked whether this regulatory mechanism might control the host response to transplanted heart allografts. We report that CD8 Treg that recognize Qa-1, the murine homolog of HLA-E, strongly inhibits host production of antibodies specific for the donor organ. Since the production of antidonor antibodies is currently a major barrier to successful transplantation, identification of this Qa-1/HLA-E-dependent pathway may pave the way to approaches to this pressing clinical problem.